Core Viewpoint - Rakovina Therapeutics Inc. has announced an upsized financing plan totaling approximately $2 million, which includes a convertible debenture and a common share private placement to support near-term operations [1][4]. Financing Details - The financing consists of a non-brokered private placement of an unsecured convertible debenture for $1.0 million, along with two million common share purchase warrants, with each warrant exercisable at $0.20 per share until January 28, 2029 [2][9]. - Concurrently, the company proposes to offer up to 8,333,334 common shares at a price of $0.12 per share, aiming for additional gross proceeds of up to approximately $1.0 million [3]. Use of Proceeds - The aggregate gross proceeds from the private placements will be utilized for near-term working capital to support ongoing corporate activities and strategic initiatives while evaluating longer-term financing alternatives [4]. Regulatory Approvals - The closing of the private placements is contingent upon obtaining all necessary corporate and regulatory approvals, including approval from the TSX Venture Exchange [5]. Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments using AI-powered drug discovery technologies, specifically targeting the DNA-damage response [6][7].

Core Insights - Rakovina Therapeutics is advancing cancer therapies through AI-enabled drug discovery, focusing on brain-penetrant inhibitors and novel ADC payloads [2][4][6] Group 1: Corporate Update - The company provided a corporate update following participation in the 9th Annual DNA Damage Response Inhibitors Summit, where its President and Chief Scientific Officer presented its AI-driven strategy [2][3] - The summit included discussions with leaders from major institutions, emphasizing the future of DDR therapeutics [3] Group 2: Competitive Advantage - Rakovina's lead kt-5000 series is designed to be dual-targeting (ATR + mTOR) and brain-penetrant, addressing the limitations of current clinical-stage candidates [4][5] - Feedback from clinical thought leaders confirmed that Rakovina's approach targets critical gaps in the market, particularly for PTEN-deficient tumors [5][9] Group 3: Novel ADC Payloads - The company received interest in its kt-3000 series as potential payloads for Antibody-Drug Conjugates (ADCs), indicating a demand for novel solutions to overcome resistance in current ADC therapies [6][9] - Rakovina plans to prioritize proof-of-concept studies to unlock partnership value in this area [6] Group 4: Strategic Validation - Industry feedback validates Rakovina's strategy of targeting PTEN-deficient tumors with brain-penetrant ATR/mTOR inhibitors, addressing gaps left by recent clinical setbacks [9]

Core Viewpoint - Rakovina Therapeutics Inc. is undergoing significant corporate updates, including leadership changes, debt restructuring, and financing initiatives to strengthen governance and enhance capital markets execution [1]. Debt Restructuring - The maturity date of the 12.0% convertible debentures, totaling $1,454,000, has been extended from January 28, 2026, to March 11, 2026, with consent from holders representing at least 66 2/3% of the outstanding principal [2][3]. - The company plans to restructure the outstanding 2023 Debentures, offering holders the option to convert their debentures into new Replacement Debentures or settle through a shares-for-debt conversion at $0.12 per share [4][5]. - An agreement in principle has been reached with an existing investor for an additional $1.0 million investment through a private placement of unsecured convertible debentures [7]. Financing Initiatives - The company proposes a concurrent private placement of up to 5,000,000 common shares at $0.12 per share, aiming for additional gross proceeds of up to $500,000 [9]. - The proceeds from the private placements will be used for near-term working capital to support ongoing corporate activities and strategic initiatives [10]. Leadership Changes - Kim Oishi has been appointed as the new Chief Executive Officer and will also join the Board of Directors, bringing extensive experience in public company leadership and capital markets strategy [11][12]. - Frank Holler has been appointed as an independent director, contributing significant expertise in life sciences and governance [16][18][21]. - Jeffrey Bacha will continue as the non-executive Chair of the Board, ensuring continuity and strategic oversight [13][15]. Board Composition - Dr. Dennis Brown has stepped down from the Board but will continue as Chair of the Scientific Advisory Committee, while Al DeLucrezia has also stepped down but will remain as an advisor [23][24]. - The Board's recent changes are aimed at enhancing governance and supporting the company's strategic initiatives in oncology [25][26]. Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments that target the DNA damage response, utilizing advanced computational chemistry and AI-enabled drug discovery platforms [27].

Core Viewpoint - Rakovina Therapeutics Inc. is expanding its collaboration with Variational AI to optimize its kt-5000 series of ATR inhibitors, aiming to accelerate the drug discovery process using AI technology [1][2]. Group 1: Collaboration Details - The new agreement focuses on lead optimization of drug candidates identified by Variational AI's Enki™ generative AI platform, with the goal of identifying a clinical candidate in months instead of years [2][3]. - Variational AI will generate and prioritize multiple optimized compound designs, while Rakovina will maintain control over which candidates to advance into laboratory testing [3] Group 2: Product Focus - Rakovina's kt-5000 program targets ATR (ataxia telangiectasia and Rad3-related), a key regulator of the DNA damage response, which is crucial for cancer cell survival under stress [4]. - The program includes small-molecule inhibitors that have shown dual ATR/mTOR activity and are designed for central nervous system (CNS) penetration, addressing limitations of existing ATR inhibitors [5]. Group 3: Strategic Insights - The collaboration aims to enhance the efficiency of identifying high-quality development candidates while reducing the time and cost associated with early-stage drug discovery [3][6]. - The use of AI in drug optimization is expected to lead to a more efficient path for Rakovina in identifying candidates for human trials [6][7]. Group 4: Company Background - Variational AI specializes in generative AI for drug discovery, focusing on small-molecule drug candidates with improved potency, selectivity, and synthesizability [7]. - Rakovina Therapeutics is dedicated to developing innovative cancer treatments through unique technologies targeting the DNA-damage response, leveraging AI for faster drug candidate optimization [8][9].

Core Insights - Rakovina Therapeutics Inc. is actively engaging with potential partners and the investment community during the J.P. Morgan Healthcare Conference scheduled for January 12-16, 2026 [1][3] - The company is focusing on AI-powered drug discovery to advance innovative cancer therapies, particularly through its proprietary platforms Deep-Docking™ and Enki™ [4][5] Company Activities - Senior members of Rakovina's executive leadership will be in San Francisco for meetings with potential partners [1] - The company will also participate in Fierce JPM Week, which is part of the broader industry programming during the conference [2] Strategic Focus - The executive chairman highlighted the importance of the JPM week for high-quality in-person partnering discussions, especially given the interest in AI drug development [3] - Recent preclinical data presented at the Society for Neuro-Oncology meeting in November 2025 indicates that Rakovina's AI-designed ATR/mTOR dual inhibitors effectively penetrate the central nervous system and match or exceed the potency of leading clinical comparators [3] Pipeline Development - Rakovina has established a pipeline of distinctive DNA-damage response inhibitors, aiming to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners [5]

Core Insights - Rakovina Therapeutics is advancing innovative cancer therapies through AI-powered drug discovery and will host a webinar on December 17, 2025 [1][2] - The webinar will feature discussions on creating CNS-penetrant, multi-target cancer therapeutics, using the AI-designed ATR/mTOR inhibitor program as a case study [2] - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [4] Company Overview - Rakovina Therapeutics focuses on developing innovative cancer treatments utilizing unique technologies for targeting the DNA-damage response, powered by AI through proprietary platforms like Deep-Docking™ and Enki™ [3][4] - The company emphasizes the accelerated pace of reviewing and optimizing drug candidates due to its AI capabilities [3] Webinar Details - The session titled "From Handshake to Breakthrough" will include a fireside discussion with leaders from Rakovina and Variational AI [2] - An open Q&A session will allow participants to engage directly with both organizations [3]

All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced its financial results for the three months ended September 30, 2025 (“Q3 2025”), and provided an update on recent corporate developments. Q3 2025 Financial Highlights Reported a net loss ...

All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced its financial results for the three months ended September 30, 2025 (“Q3 2025”), and provided an update on recent corporate developments. Q3 2025 Financial Highlights Reported a net loss ...

Core Viewpoint - Rakovina Therapeutics Inc. has announced the extension of the maturity date for its 12.0% convertible debentures from November 29, 2025, to January 28, 2026, following consent from debentureholders representing at least 66 2/3% of the outstanding principal [1][2] Group 1: Convertible Debentures - The total principal amount of the convertible debentures is $1,454,000.00, and the interest rate will remain at 12.0% during the extension period [1][2] - The extension is subject to approval from the TSX Venture Exchange [2] Group 2: Related Party Disclosure - Certain directors of the company own approximately $100,000 principal amount of the convertible debentures, representing about 6.9% of the outstanding principal [3] - The participation of these directors in the extension is classified as a "related party transaction" under applicable regulations, and the company has relied on exemptions from formal valuation and minority shareholder approval requirements [3] Group 3: Warrant Incentive Program - The company's early exercise warrant incentive program expired on September 2, 2025, with no warrants being exercised [4] Group 4: Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments using AI-powered technologies for targeting DNA-damage response [5][6] - The company aims to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners [6]

Core Viewpoint - Rakovina Therapeutics Inc. has announced the extension of the maturity date for its 12.0% convertible debentures from November 29, 2025, to January 28, 2026, following consent from debentureholders representing at least 66 2/3% of the outstanding principal [1][2] Group 1: Convertible Debentures - The total principal amount of the convertible debentures is $1,454,000.00, and the interest rate will remain at 12.0% during the extension period [1][2] - The extension is subject to approval from the TSX Venture Exchange [2] Group 2: Related Party Disclosure - Certain directors of the company own approximately $100,000 principal amount of the convertible debentures, representing about 6.9% of the outstanding principal [3] - The participation of these directors in the extension is classified as a "related party transaction" under applicable regulations, and the company has relied on exemptions from formal valuation and minority shareholder approval requirements [3] Group 3: Warrant Incentive Program - The early exercise warrant incentive program expired on September 2, 2025, with no warrants being exercised [4] Group 4: Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments using AI-powered technologies for targeting DNA-damage response [5][6] - The company aims to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners [6]